Gilead Makes Executive Promotions

Robin Washington, chief financial officer, has been promoted to executive vice president at Gilead Sciences. Paul Carter, formerly senior vice president, International Commercial Operations, has been promoted to executive vice president, responsible for Gilead’s worldwide commercial organization, and John McHutchison, MD, formerly senior vice president, Liver Disease Therapeutics, has been promoted to executive vice president and will assume additional responsibility for clinical development programs in the areas of oncology, respiratory diseases and inflammation.
 
Ms. Washington oversees the company’s finance, information technology and investor relations functions, reporting to John Milligan, PhD, Gilead’s president and chief operating officer. She joined the company in 2008 as senior vice president and chief financial officer. Prior to joining Gilead, Ms. Washington was chief financial officer of Hyperion Solutions, which was acquired by Oracle Corporation in March 2007.
 
Mr. Carter joined the company in April 2006 to head its European commercial organization, and then assumed additional responsibility for operations outside of Europe and North America. Prior to joining the company, Mr. Carter spent 15 years in the pharmaceutical industry with GlaxoSmithKline and its legacy companies and held positions of increasing responsibility as general manager in Europe and later as a regional head of the international business in Asia.
 
Dr. McHutchison will continue to report to Norbert Bischofberger, Ph.D., executive vice president, R&D and chief scientific officer. He joined Gilead in 2010 as senior vice president, Liver Disease Therapeutics. Prior to joining the company, Dr. McHutchison worked at Duke University Medical Center, where he served as associate director of the Duke Clinical Research Institute.  
 
“Robin, Paul and John have made significant contributions to Gilead, each demonstrating a commitment to improving systems and processes and advancing programs that will allow us to meet the needs of patients as quickly as possible,” said John C. Martin, Ph.D., chairman and chief executive officer, Gilead Sciences. “They have each built strong, capable teams and have helped Gilead navigate an increasingly complex environment as we expand geographically and into new therapeutic categories. Their leadership and vision will help ensure Gilead is able to achieve our goals and reach more patients in need around the world.”